



(11) **EP 2 808 343 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

- (15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73
- (51) Int Cl.:
C07K 16/22 ^(2006.01) **C07K 16/24** ^(2006.01)
C07K 16/28 ^(2006.01)
- (48) Corrigendum issued on:
15.01.2020 Bulletin 2020/03
- (45) Date of publication and mention of the grant of the patent:
15.05.2019 Bulletin 2019/20
- (21) Application number: **14171372.7**
- (22) Date of filing: **22.12.2008**

(54) **Fc variants with altered binding to FcRn**
Fc-Varianten mit veränderter Bindung zu FcRn
Variantes Fc avec liaison altérée en FcRn

- | | |
|---|---|
| <p>(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR</p> <p>(30) Priority: 26.12.2007 US 16793 P
25.02.2008 US 31353 P
18.04.2008 US 46353 P
02.05.2008 US 50172 P
10.07.2008 US 79779 P
22.09.2008 US 99178 P</p> <p>(43) Date of publication of application:
03.12.2014 Bulletin 2014/49</p> <p>(60) Divisional application:
19169906.5 / 3 575 317</p> <p>(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:
08866130.1 / 2 235 059</p> | <p>(73) Proprietor: Xencor, Inc.
Monrovia, CA 91016 (US)</p> <p>(72) Inventors:
• Chamberlain, Aaron
San Diego, CA 92106 (US)
• Dahiyat, Bassil
Altadena, CA 91001 (US)
• Desjarlais, John Rudolph
Pasadena, CA 91104 (US)
• Karki, Sher Bahadur
Pomona, CA 91767 (US)
• Lazar, Gregory Alan
Indianapolis, IN 46220 (US)</p> <p>(74) Representative: HGF Limited
Saviour House
9 St. Saviourgate
York YO1 8NQ (GB)</p> <p>(56) References cited:
US-A1- 2006 173 170</p> |
|---|---|

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 808 343 B8

- DALL'ACQUA W F ET AL: "Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences", JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 169, no. 9, 1 November 2002 (2002-11-01), pages 5171-5180, XP002384463, ISSN: 0022-1767
- SHIELDS R L ET AL: "High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BIRMINGHAM, US, vol. 276, no. 9, 2 March 2001 (2001-03-02), pages 6591-6604, XP002495886, ISSN: 0021-9258 [retrieved on 2000-11-28]
- GHETIE V ET AL: "INCREASING THE SERUM PERSISTENCE OF AN IGG FRAGMENT BY RANDOM MUTAGENESIS", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 15, no. 7, 1 January 1997 (1997-01-01), pages 637-640, XP000876642, ISSN: 1087-0156
- HINTON PAUL R ET AL: "An engineered human IgG1 antibody with longer serum half-life", JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 176, no. 1, 1 January 2006 (2006-01-01), pages 346-356, XP002482524, ISSN: 0022-1767